Publications by authors named "F Alvarez-Mancenido"
Article Synopsis
- The study investigates the effectiveness and tolerability of different chemotherapy regimens (FOLFOX, CAPOX, CP, and FP) for treating HER2-negative advanced esophagogastric cancer, using data from the AGAMENON-SEOM Spanish registry between 2008 and 2021.
- Results indicate that FOLFOX significantly improves progression-free survival (PFS) compared to the CP regimen, although treatment durations were similar among all groups.
- Adverse effects varied by regimen, with higher rates of fatigue and neuropathy seen in FOLFOX, while CP showed notable incidences of hand-foot syndrome and thromboembolic events.
Introduction: The mechanism of action of immune checkpoints inhibitors hinders the writing of rational statistical analysis plans for phase III randomised clinical trials (RCTs) because of their unpredictable dynamic effects. The purpose is to illustrate the advantages of Bayesian reporting of treatment efficacy analysis in immunotherapy RCTs, in contrast to frequentist reporting.
Method: Fourteen RCTs (one with two pairwise comparisons) that failed to achieve their primary objective (overall survival, OS) were selected.
Background: Advanced esophageal adenocarcinoma (EAC) is generally treated similarly to advanced gastroesophageal junction (GEJ-AC) and gastric (GAC) adenocarcinomas, although GAC clinical trials rarely include EAC. This work sought to compare clinical characteristics and treatment outcomes of advanced EAC with those of GEJ-AC and GAC and examine prognostic factors.
Patients And Methods: Participants comprised patients with advanced EAC, intestinal GEJ-AC, and GAC treated with platin and fluoropyrimidine (plus trastuzumab when HER2 status was positive).
Erratum to "Critical reappraisal of phase III trials with immune checkpoint inhibitors in non-proportional hazards settings" [Eur J Cancer 136 (September 2020) 159-168].
Eur J Cancer
January 2021
Background: The dynamic effects of immune checkpoint inhibitors (ICIs) are a challenge when designing and analysing data in non-proportional hazards (PH) scenarios. Herein, we present the risk of making type II errors, affecting pharmacotherapeutic development when methods that assume constant effects are applied.
Patients And Methods: Individual patient data from six clinical trials (KEYNOTE-062/061, IMvigor211, CA184-143 y CheckMate-057/037) were extracted.